Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

Michel, Laura L.; Ziegler, Philipp; Kreis, Philipp; Hartkopf, Andreas D.; Wallwiener, Markus; Haeberle, Lothar; John, Nelson; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Ettl, Johannes; Lueftner, Diana; Mueller, Volkmar; Belleville, Erik; Wimberger, Pauline; Enzinger, Hans-Martin; Huebner, Hanna; Uhrig, Sabrina; Hack, Carolin C.; Krabisch, Petra; Fasching, Peter A.; Wuerstlein, Rachel; Untch, Michael; Ditsch, Nina; Hein, Alexander; Janni, Wolfgang; Taran, Florin-Andrei; Lux, Michael P.; Wallwiener, Diethelm; Brucker, Sara Y.; Fehm, Tanja N.; Schneeweiss, Andreas; Goossens, Chloe; Engler, Tobias

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

Autor(en):

Michel, Laura L.; Ziegler, Philipp; Kreis, Philipp; Hartkopf, Andreas D.; Wallwiener, Markus; Haeberle, Lothar; John, Nelson; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Ettl, Johannes; Lueftner, Diana; Mueller, Volkmar; Belleville, Erik; Wimberger, Pauline; Enzinger, Hans-Martin; Huebner, Hanna; Uhrig, Sabrina; Hack, Carolin C.; Krabisch, Petra; Fasching, Peter A.; Wuerstlein, Rachel; Untch, Michael; Ditsch, Nina; Hein, Alexander; Janni, Wolfgang; Taran, Florin-Andrei; Lux, Michael P.; Wallwiener, Diethelm; Brucker, Sara Y.; Fehm, Tanja N.; Schneeweiss, Andreas; Goossens, Chloe; Engler, Tobias

Tübinger Autor(en):

Wallwiener, Diethelm
Engler, Tobias
Hartkopf, Andreas
Brucker, Sara

Erschienen in:

European Journal of Cancer (2025), Bd. 227, Article 115689

Verlagsangabe:

London : Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.ejca.2025.115689

ISSN:

0959-8049